BRYREL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Bryrel, and when can generic versions of Bryrel launch?
Bryrel is a drug marketed by Sanofi Aventis Us and is included in one NDA.
The generic ingredient in BRYREL is piperazine citrate. There are eighteen drug master file entries for this compound. Additional details are available on the piperazine citrate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for BRYREL?
- What are the global sales for BRYREL?
- What is Average Wholesale Price for BRYREL?
Summary for BRYREL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 50 |
| DailyMed Link: | BRYREL at DailyMed |
US Patents and Regulatory Information for BRYREL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | BRYREL | piperazine citrate | SYRUP;ORAL | 017796-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
